Headlines warning about “Ozempic blindness” may be frightening to the millions of people taking a GLP-1 drug to treat Type 2 diabetes or for weight loss.

It's not an official diagnosis, but an informal term that refers to a potentially higher risk of eye problems and vision loss linked to GLP-1 drugs like semaglutide — the active ingredient in Ozempic and Wegovy — according to some recent studies.

There have been lawsuits filed against Novo Nordisk , the maker of both drugs, accusing the company of failing to warn patients about the risk of an eye injury known as NAION.

But Novo Nordisk says his condition is a “very rare eye disease” and is not an adverse drug reaction for semaglutide.

So is there cause for alarm?

Experts say no, based on current evidence. But they note the importan

See Full Page